Progenity to Participate in the H.C. Wainwright BIOCONNECT Virtual Conference

Rhea-AI Summary

Progenity, Inc. (Nasdaq: PROG) announced its participation in the H.C. Wainwright BIOCONNECT Virtual Conference with a pre-recorded presentation available on January 10, 2022. The presentation will be accessible at 7 a.m. Eastern / 4 a.m. Pacific on the conference website and on Progenity's Investor section.

Progenity focuses on oral biotherapeutics and aims to innovate in gastrointestinal and women's health through a multi-omics approach for precise diagnostics and localized treatment solutions.

SAN DIEGO, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Progenity, Inc. (Nasdaq: PROG), a biotechnology company innovating in the field of oral biotherapeutics for gastrointestinal health and beyond, today announced that the company will participate in a pre-recorded presentation at the H.C. Wainwright BIOCONNECT Virtual Conference. The presentation will be available on the conference website beginning at 7 a.m. Eastern / 4 a.m. Pacific on January 10, 2022.

A link to the presentation will also be available at the same time in the Investors section of the company’s website at progenity.com/presentations.

About Progenity

Progenity, Inc. is a biotechnology company innovating in the fields of women’s health, gastrointestinal health and oral biotherapeutics. Progenity applies a multi-omics approach, combining genomics, epigenomics, proteomics, and metabolomics to its molecular testing products and to the development of a suite of investigational ingestible devices designed to provide precise diagnostic sampling and drug delivery solutions. Progenity’s vision is to transform healthcare to become more precise and personal by improving diagnoses of disease and improving patient outcomes through localized treatment with targeted therapies.

For more information visit www.progenity.com, or follow the company on LinkedIn or Twitter.

Investor Contact:
Robert Uhl
Managing Director, ICR Westwicke
ir@progenity.com
(619) 228-5886

Media Contact:
Kate Blom-Lowery
CG Life
media@progenity.com
(619) 743-6294

FAQ

When will Progenity present at the H.C. Wainwright BIOCONNECT Virtual Conference?

Progenity will present on January 10, 2022, with the presentation available starting at 7 a.m. Eastern / 4 a.m. Pacific.

Where can I view Progenity's presentation from the BIOCONNECT Virtual Conference?

The presentation will be available on the conference website and in the Investors section of Progenity's website.

What is Progenity focusing on in its biotechnology innovations?

Progenity focuses on oral biotherapeutics for gastrointestinal health and women's health, using a multi-omics approach.

What is the stock symbol for Progenity?

The stock symbol for Progenity is PROG.